ABBV

Research snapshot

• Overall rating: 82/100, bullish
• Market-cap class: Mega cap
• Primary view: Skyrizi, Rinvoq, neuroscience, and pipeline assets have more than replaced current Humira erosion, but high debt, acquisition spending, and product concentration require disciplined execution
• Data date: Quarter ended June 30, 2026; technical data updates after every completed daily candle

The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.

1. Company overview

AbbVie develops and sells medicines across immunology, neuroscience, oncology, eye care, and other specialty areas. Its Allergan Aesthetics portfolio includes Botox Cosmetic, Juvederm, and related products.

The business is organized around several therapeutic portfolios:

• Immunology: Skyrizi, Rinvoq, and declining Humira.
• Neuroscience: Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev.
• Oncology: Venclexta, Imbruvica, Elahere, Epkinly, and pipeline programs.
• Aesthetics: Botox Cosmetic, Juvederm, Skinvive, and other products.

AbbVie's strategy is to use strong cash flow from established products to fund research, licensing, acquisitions, dividends, and new commercial platforms that can replace medicines losing exclusivity.

2. Fundamentals

Growth and profitability

Second-quarter revenue increased 10.2% to $16.99 billion, or 9.5% operationally. GAAP EPS increased to $2.03, while adjusted EPS increased 22.9% to $3.65.

GAAP gross margin was 74.7%, and adjusted gross margin was 84.7%. GAAP operating margin reached 37.9%, while adjusted operating margin was 48.3%. The adjusted figures exclude intangible amortization, contingent-consideration changes, and other specified items.

Immunology revenue increased 15.1% to $8.79 billion. Skyrizi increased 24.4% to $5.51 billion, and Rinvoq increased 24.5% to $2.53 billion. Humira declined 35.9% to $756 million.

Neuroscience revenue increased 20.3% to $3.23 billion, led by Vraylar, Botox Therapeutic, migraine products, and Vyalev. Oncology declined 1.5% to $1.65 billion as Imbruvica weakness offset Venclexta and Elahere growth. Aesthetics was approximately flat at $1.28 billion.

Management updated full-year adjusted EPS guidance to $13.87 to $14.07, including expected dilution from the proposed Apogee Therapeutics acquisition and year-to-date acquired research expenses.

Balance sheet and cash flow

• Cash and equivalents totaled $6.57 billion.
• Current and long-term debt totaled approximately $70.82 billion.
• Six-month operating cash flow was $7.27 billion.
• Capital expenditures were $587 million.
• Estimated six-month free cash flow was approximately $6.68 billion.
• Dividend payments reached $6.2 billion during the first six months.
• AbbVie repurchased $1.1 billion of stock.
• The proposed Apogee transaction has an equity value of approximately $10.9 billion and is supported by a new $10 billion term-loan facility.

Cash generation is strong, but debt, dividends, contingent payments, acquisitions, and pipeline investment leave less room for error than the headline free cash flow suggests.

Valuation

Near $246 per share, AbbVie's equity value was approximately $436 billion. The headline trailing P/E was near 70 times because GAAP earnings include large contingent-consideration and acquisition-related expenses. The stock traded near 17.6 times the midpoint of 2026 adjusted EPS guidance.

The adjusted valuation is reasonable if Skyrizi, Rinvoq, and neuroscience continue growing and acquired assets produce returns. Investors should not ignore real cash payments, debt, dilution, and research costs simply because some are excluded from adjusted EPS.

3. Technical analysis

AbbVie's live panel recalculates its EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, resistance, and trend after each completed daily candle. Drug approvals, trial data, patent decisions, and acquisitions can cause large gaps.

4. Smart money concepts

The automated panel estimates fair value gaps, order blocks, breaks of structure, changes of character, and liquidity zones. Detected areas should be treated as chart references and confirmed with price action and volume.

5. Growth drivers and catalysts

• Skyrizi: Continued share gains and label expansion can extend immunology growth.
• Rinvoq: New indications and international approvals broaden the patient opportunity.
• Neuroscience: Vraylar, Botox, migraine products, and Vyalev provide strong diversification.
• Oncology pipeline: Elahere, Epkinly, Decnupaz, ADCs, and T-cell engagers provide optionality.
• Apogee acquisition: Zumilokibart and other candidates can deepen the long-term immunology pipeline.
• Aesthetics innovation: New indications and shorter-duration toxin products can improve a currently slow portfolio.
• Dividend: A large recurring dividend supports total returns if cash flow remains strong.

The main checkpoints are Skyrizi and Rinvoq growth, Humira erosion, neuroscience growth, oncology performance, Apogee closing and data, debt, and dividend coverage.

6. Risks

• Product concentration: Skyrizi and Rinvoq now carry a large share of growth expectations.
• Patent and biosimilar risk: Humira's decline shows how quickly exclusivity losses can affect revenue.
• Clinical risk: Pipeline failures or safety findings can destroy expected asset value.
• Acquisition risk: Apogee and other deals may fail to produce projected approvals or sales.
• Debt: Existing leverage and acquisition financing reduce flexibility.
• Adjusted accounting: Amortization, contingent consideration, and acquired research costs create a large GAAP gap.
• Drug pricing: Government and insurer actions can reduce prices and coverage.
• Oncology weakness: Imbruvica decline is currently offsetting growth elsewhere in the portfolio.
• Aesthetics sensitivity: Consumer spending and competition affect optional procedures.
• Dividend coverage: Current free cash flow only modestly exceeds dividend payments before acquisitions and other uses.

7. Scorecard and final view

• Fundamentals: 92/100
• Growth and catalysts: 91/100
• Valuation: 75/100
• Technicals: 84/100
• Risk control: 60/100
• Overall: 82/100

Final view: AbbVie earns a bullish 82 because Skyrizi, Rinvoq, neuroscience growth, margins, free cash flow, pipeline depth, and an adjusted valuation near 18 times earnings create a strong thesis. Debt, acquisitions, product concentration, accounting adjustments, clinical risk, and tight dividend coverage prevent a higher score.

Sources and methodology

• AbbVie Q2 2026 earnings release filed with the SEC
• AbbVie Q2 2026 Form 10-Q
• Price snapshot from Finnhub. Valuation estimates use the market price and company-reported financials. The live technical panel recalculates from the latest completed daily market candle.